TG Therapeutics, Inc.

NASDAQ:TGTX

Biotechnology

Healthcare
$66.12 +2.00%

+$1.03 today

Market cap
$9.99B
Beta
1.68
P/E (TTM)
16.4
EPS (TTM)
$3.20
52W Low $25.28High $53.98

Volume 1.87M

Average 2.15M

TGTX EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

TG Therapeutics, Inc.NASDAQ: TGTX

EBITDA · Q3 FY2026 · quarter ended Sep 2026

EBITDA growth accelerates

Q3 FY2026 EBITDA of $89.75M rose 174.5% year over year, ahead of the +66.0% change in trailing-twelve-month EBITDA. Sequentially, it rose 312.3% from the prior quarter.

Context

  • EBITDA amounted to 21.8% of revenue in FY2025, up 6.6 pp from a year earlier.
  • EBITDA increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 5 analysts of $216.14M (+60.9%) for the fiscal year ending Dec 2026, a slowdown from the +169.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$89.75M+312.3% QoQ
Last fiscal yearDec 2025
$134.36M+169.2% YoY
LTMSep 2026
$191.33M+66.0% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+174.5%-254.7%-429.2 pp
1 year+169.2%+60.9%-108.4 pp
3-year CAGR—+73.7%—
5-year CAGR+51.3%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
134.36M USD
Year-over-year change
+169.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How TGTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +66.0% is the highest of 7, against a peer median of -4.7%.
  • EBITDA amounts to 21.3% of revenue for TGTX, versus a peer median of 117.7%.
TGTX Competitors
EBITDA for TGTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GMABGenmab A/SLTM Jun 2026$1.22B USD—-43.3%29.5%
TGTXTG Therapeutics, Inc.LTM Sep 2026$191.33M USD+66.0%—21.3%
ADAGAdagene Inc.LTM Jun 2024-$36.06M USD——4420.7%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026-$42.27M USD-2.3%——
IPHAInnate Pharma S.A.FY2025-€43.65M EUR+7.0%—1566.1%
MGNXMacroGenics, Inc.LTM Mar 2026-$50.64M USD-7.0%—32.2%
ADCTADC Therapeutics S.A.LTM Mar 2026-$83.2M USD+13.7%—105.1%
XNCRXencor, Inc.LTM Jun 2026-$123.6M USD-14.3%—117.7%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-$305.37M USD-38.1%—272652.7%
Peer median (excluding TGTX) —-4.7%-43.3%117.7%

Competitors are the stored peer set for TGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.69M2.79M233.66M329M616.29M
Cost of Revenue790K265K14.13M38.49M100.71M
Gross Profit5.9M2.52M219.53M290.52M515.57M
Gross Margin88.2%90.5%94.0%88.3%83.7%
Research & Development222.58M125.35M76.19M94.29M160.22M
Selling, General & Admin128.09M95.48M122.71M154.3M232.03M
Operating Expenses350.67M220.84M198.9M248.59M392.25M
Depreciation & Amortization494K515K423K280K244K
EBITDA(341.97M)(213.11M)26.1M49.9M134.36M
EBITDA Margin-5112.4%-7651.9%11.2%15.2%21.8%
Operating Income(344.77M)(218.32M)20.63M41.93M123.32M
Operating Margin-5154.3%-7839.0%8.8%12.7%20.0%
Interest Income00000
Interest Expense5.64M10.19M12.62M24.03M26.73M
Other Income / Expenses(3.33M)(5.5M)(7.57M)(16.34M)(15.93M)
Income Before Tax(348.1M)(223.81M)13.06M25.59M107.39M
Pre-Tax Margin-5204.1%-8036.3%5.6%7.8%17.4%
Income Tax Expense00390K2.21M(339.79M)
Net Income(348.1M)(223.81M)12.67M23.38M447.18M
Net Margin-5204.1%-8036.3%5.4%7.1%72.6%
EPS (Basic)(2.63)(1.46)0.090.163.10
EPS (Diluted)(2.63)(1.46)0.090.152.77
Weighted Avg Shares132.22M135.41M141.96M145.32M144.32M
Weighted Avg Shares (Diluted)132.22M135.41M148.51M160.34M161.41M

TG Therapeutics, Inc.

NASDAQ:TGTX

Intrinsic Alpha fair value

Locked

Current Price

$66.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.